Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SOPHiA GENETICS SA

Market Cap 350M 302M 278M 261M 490M 33.18B 496M 3.29B 1.28B 16.21B 1.31B 1.29B 56.16B P/E Ratio 2026 *
-5.52x
P/E Ratio 2027 * -7.21x
Enterprise Value 350M 302M 278M 261M 490M 33.18B 496M 3.29B 1.28B 16.21B 1.31B 1.29B 56.16B EV / Sales 2026 *
3.75x
EV / Sales 2027 * 3.12x
Free-Float
73.68%
Yield 2026 *
-
Yield 2027 * -
1 day+2.39%
1 week-0.47%
1 month+7.54%
3 months+9.18%
6 months+5.94%
Current year+10.31%
1 week 4.18
Extreme 4.18
4.6
1 month 3.94
Extreme 3.94
4.6
Current year 3.46
Extreme 3.46
4.82
1 year 3.34
Extreme 3.34
4.82
3 years 2.08
Extreme 2.08
5.1
5 years 2.08
Extreme 2.08
5.1
10 years 2.08
Extreme 2.08
5.1
Manager TitleAgeSince
Chief Executive Officer 47 2010-12-31
Director of Finance/CFO 64 2024-11-04
President 46 2024-11-04
Director TitleAgeSince
Director/Board Member 47 2011-02-28
Director/Board Member 57 2014-05-31
Chairman 61 2020-01-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.39%-0.47% - - 350M
+1.65%-6.05%-42.60%-16.57% 25.92B
+0.34%-0.66%-39.17%+154.09% 12.08B
-3.25%-0.27%-6.88%+51.79% 6.19B
-1.26%+16.80% - - 2.87B
+5.71%-7.00%+36.72%-44.63% 1.72B
+9.69%+5.52% - - 1.59B
0.00%-4.31%-33.27%-59.89% 813M
-2.36%-1.92%-29.85%+203.67% 803M
-1.76%-1.36%-36.05%-41.12% 724M
Average +1.12%-0.89%-21.59%+35.34% 5.86B
Weighted average by Cap. +0.87%-3.18%-33.86%+36.51%

Financials

2026 *2027 *
Net sales 93.4M 80.59M 74.15M 69.68M 131M 8.85B 132M 877M 342M 4.32B 350M 343M 14.97B 112M 96.96M 89.21M 83.83M 157M 10.64B 159M 1.06B 412M 5.2B 422M 413M 18.01B
Net income -64.65M -55.78M -51.32M -48.23M -90.42M -6.12B -91.44M -607M -237M -2.99B -243M -237M -10.36B -50.72M -43.76M -40.27M -37.84M -70.94M -4.8B -71.74M -476M -186M -2.35B -190M -186M -8.13B
Net Debt - -
Logo SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Employees
415
Date Price Change
26-06-15 4.280 +2.39%
26-06-12 4.180 -6.28%
26-06-11 4.460 +0.90%
26-06-10 4.420 -3.91%
26-06-09 4.600 +2.22%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.880USD
Average target price
8.000USD
Spread / Average Target
+63.93%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!